Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seeing something new or with new eyes?

British journal of haematology·2025
Same author

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

British journal of haematology·2023
Same author

Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.

British journal of haematology·2023
Same author

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.

British journal of haematology·2022
Same author

Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.

British journal of haematology·2021
Same author

Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup> -mutant acute myeloid leukaemia.

British journal of haematology·2021

Related Experiment Video

Updated: Aug 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

What drives CAR-T emergent cytopenia?

Robert K Hills1

  • 1Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.

British Journal of Haematology
|April 3, 2023
PubMed
Summary

Prolonged cytopenia after CAR-T cell therapy may be predicted by bone marrow niche alterations present before treatment. This finding offers insights into managing this serious side effect and improving patient outcomes.

Keywords:
ALLCAR-T emergent cytopeniarefractory haematological malignancies

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

695
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

970

Related Experiment Videos

Last Updated: Aug 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

695
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

970

Area of Science:

  • Hematology
  • Immunotherapy
  • Oncology

Background:

  • Prolonged cytopenia is a recognized complication following chimeric antigen receptor T-cell (CAR-T) therapy.
  • The underlying causes and clinical significance of persistent cytopenia post-CAR-T therapy remain incompletely understood.

Purpose of the Study:

  • To investigate the relationship between the bone marrow microenvironment and prolonged cytopenia after CAR-T cell therapy.
  • To identify potential predictors of sustained hematologic toxicity in patients undergoing CAR-T treatment.

Main Methods:

  • Analysis of bone marrow niche characteristics prior to CAR-T cell administration.
  • Correlation of pre-treatment bone marrow alterations with the development of prolonged cytopenia.

Main Results:

  • Alterations in the bone marrow niche before CAR-T therapy were associated with prolonged cytopenia.
  • These pre-existing bone marrow microenvironment changes may serve as a predictor for this adverse event.

Conclusions:

  • Pre-treatment bone marrow microenvironment status is a potential factor influencing the occurrence of prolonged cytopenia after CAR-T therapy.
  • Identifying these alterations could aid in predicting and potentially mitigating this serious treatment complication.